Since APP palmitoylation enhances amyloidogenic processing by targeting APP to lipid rafts and enhancing its BACE1-mediated cleavage [253], inhibition of palmitoylation of APP formation by specific palmitoylation inhibitors was proposed as a strategy for the prevention and/or treatment of Alzheimer’s disease [253]. This evidence concerns the gene APP and Alzheimer disease.